In Depth 12 Sep 2024
New treatments being developed for schizophrenia
Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.
In Depth
- Latest Posts
In Depth 5 Sep 2024
The biggest private biotech investments in August 2024
The companies Borealis Biosciences, Outpace Bio, and Halda Therapeutics bagged the biggest private biotech investments in August 2024.
In Depth 3 Sep 2024
Adaptimmune: The long road toward finally bringing the first TCR-T cell therapy to the market
Find out about Adaptimmune’s long – and somewhat bumpy – road toward bringing the first TCR-T therapy to the market.
In Depth 21 Aug 2024
The promise of antisense oligonucleotides in precision medicine
Find out all about antisense oligonucleotides, which have gained a lot of popularity in recent years and could treat numerous diseases.
In Depth 9 Aug 2024
The therapeutic potential of circular RNA: Could it soon trump mRNA technology?
Find out about circular RNA, an emerging technology that could hold a lot of promise for next-generation vaccines and gene therapies.
In Depth 6 Aug 2024
The biggest private biotech investments in July 2024
The companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest private biotech investments in July 2024.
ADVERTISEMENT
ADVERTISEMENT
In Depth 1 Aug 2024
CureVac: From a failed drug to a €1.45 billion deal
In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around.
In Depth 30 Jul 2024
Why is the immunology and inflammation market suddenly attracting a wave of investment?
Discover why the immunology and inflammation market has recently been attracting a major wave of investment.
In Depth 25 Jul 2024
The future of inflammatory bowel disease treatment: what is on the horizon?
Ongoing clinical trials aim to address inflammatory bowel disease, which is caused by an overactive immune system that causes symptoms affecting the gut.
In Depth 24 Jul 2024
Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?
Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market.
In Depth 18 Jul 2024
Lenacapavir: Can Gilead’s drug end the HIV pandemic?
Discover more about Gilead’s lenacapavir, which recently demonstrated 100% efficacy for HIV prevention in a phase 3 trial.
In Depth 15 Jul 2024
Fighting EEHV in elephants: How mRNA vaccines can offer hope against viruses affecting animals
Discover how a new mRNA vaccine could help to tackle EEHV in elephants, which is a number one killer of Asian elephant calves.
ADVERTISEMENT
